The resulting multivalent Rha‐7D12 conjugates were used to investigate the structure‐activity relationship in terms of recruiting endogenous anti‐Rha antibody capability and eliciting Fc effector functions against EGFR‐positive cancer cells (Figure 1A). This evidence concerns the gene DHX9 and cancer.